Answers are grounded in this paper and cite their sources.
Premature ovarian insufficiency (POI) is a condition characterized by the early depletion of ovarian follicles, leading to infertility and various systemic complications. Granulosa cell (GC) pyroptosis contributes significantly to the pathogenesis of POI. Orexin A, a neuropeptide involved in regulating wakefulness, has been shown to exert anti-inflammatory effects. This study investigates the potential protective role of orexin A in POI by targeting pyroptosis in ovarian GCs. We found that orexin A significantly reduced oxidative stress and the activation of the NLRP3 inflammasome in POI mice, thereby improving serum hormone levels and follicle count. Additionally, orexin A inhibited pyroptosis in cyclophosphamide (CTX)-treated KGN cells by downregulating NLRP3, caspase-1, and gasdermin D (GSDMD) expression. These effects were mediated through the activation of adenosine 5'-monophosphate-activated protein kinase (AMPK) signaling, which is known to regulate cellular metabolism and suppress inflammasome activation. In conclusion, orexin A has the potential to alleviate POI by inhibiting NOD-like receptor thermal protein domain-associated protein 3 (NLRP3) inflammasome-mediated pyroptosis and activating AMPK signaling, offering a promising therapeutic approach for POI treatment.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: